Biostage, Inc. (NASDAQ:BSTG) insider Saverio Lafrancesca purchased 100,000 shares of the company’s stock in a transaction that occurred on Thursday, August 24th. The stock was acquired at an average price of $0.37 per share, for a total transaction of $37,000.00. Following the purchase, the insider now owns 293,998 shares in the company, valued at approximately $108,779.26. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Saverio Lafrancesca also recently made the following trade(s):
- On Wednesday, August 23rd, Saverio Lafrancesca purchased 150,000 shares of Biostage stock. The stock was acquired at an average price of $0.32 per share, for a total transaction of $48,000.00.
Biostage, Inc. (BSTG) traded down 3.8356% during midday trading on Friday, reaching $0.3159. The company had a trading volume of 1,874,116 shares. The stock’s 50 day moving average is $0.45 and its 200 day moving average is $0.37. Biostage, Inc. has a 12-month low of $0.22 and a 12-month high of $1.42. The firm’s market capitalization is $12.30 million.
Biostage (NASDAQ:BSTG) last announced its earnings results on Monday, August 14th. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.07) by $0.03. Equities research analysts expect that Biostage, Inc. will post ($0.42) earnings per share for the current year.
A hedge fund recently raised its stake in Biostage stock. Vanguard Group Inc. raised its stake in shares of Biostage, Inc. (NASDAQ:BSTG) by 4.0% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 773,820 shares of the biotechnology company’s stock after buying an additional 29,902 shares during the period. Vanguard Group Inc. owned about 2.08% of Biostage worth $319,000 at the end of the most recent reporting period. Institutional investors own 6.99% of the company’s stock.
Separately, Maxim Group restated a “hold” rating on shares of Biostage in a research note on Monday, August 7th.
About Biostage
Biostage, Inc, formerly Harvard Apparatus Regenerative Technology, Inc, is a biotechnology company. The Company is engaged in developing bioengineered organ implants based on its Cellframe technology. Its Cellframe technology consists of a biocompatible scaffold that is seeded with the recipient’s own cells.
Receive News & Ratings for Biostage Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biostage Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
